Clinical Studies
Our clinical studies are evaluating a new investigational topical medication (active ingredient combined with a proprietary polymer delivery system) designed to treat Netherton Syndrome (NS). If you or your child has been clinically diagnosed with NS and is in good general health, you or they may qualify to participate. QRX003 is a topical lotion applied twice daily (BID) for 12 weeks to Netherton syndrome (NS) diseased skin in all affected areas of the body excluding the scalp (the Treatment Area), totaling approximately 50% Body Surface Area (BSA) or more.
Study #1
(CL-QRX003-002)
Brief Summary - A multicenter, open label study of QRX003 lotion in subjects with Netherton Syndrome to assess the safety, tolerability, and efficacy of QRX003 lotion (4%) when added to off-label systemic biologics treatment.
Learn More about the Study - NCT05789056 - https://clinicaltrials.gov/study/NCT05789056?cond=Netherton%20Syndrome&viewType=Card&rank=6
Study #2
(CL-QRX003-003)
Brief Summary - A single center, open label, expanded access study of QRX003 lotion in subjects with Netherton Syndrome to assess the safety, tolerability, and efficacy of QRX003 lotion (4%) when added to off-label regimen, including other topical over-the-counter (OTC), prescription treatments, and/or systemic therapies.
Learn More about the Study - NCT06953466 https://clinicaltrials.gov/study/NCT06953466?cond=Netherton%20Syndrome&viewType=Card&rank=3
Study #3
(CL-QRX003-004)
Brief Summary – A multicenter, open-label study to evaluate the safety, tolerability, and efficacy of QRX003 lotion 4%.
Learn More about the Study - NCT07538583 - https://clinicaltrials.gov/study/NCT07538583?term=QRX003&viewType=Card&rank=2
Qualified participants will receive study-related examinations by a physician, genetic testing to confirm Netherton Syndrome, all study visits, and study drugs. Compensation for your time and study participation will be provided. Additionally, if significant travel is necessary to reach a clinical study site, travel expenses such as airfare, meals, and lodging may be reimbursed for the patient and one accompanying parent (in the case of a child).
If you are interested in participating in one of these exciting studies, please take a brief survey to see if you qualify
https://www.research.net/r/NSclinicalstudy or call
(858) 571-1800 ext 151 or Email:Bcooke@therapeuticsinc.com
Thank you for your interest in this investigational study for NS.
